- Home
- ALLR vs AYTU Comparison
ALLR vs AYTU Comparison
Compare ALLR & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- AYTU
- Stock Information
- Founded
- ALLR 2004
- AYTU N/A
- Country
- ALLR United States
- AYTU United States
- Employees
- ALLR N/A
- AYTU N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- AYTU Health Care
- Exchange
- ALLR Nasdaq
- AYTU Nasdaq
- Market Cap
- ALLR 21.8M
- AYTU 23.0M
- IPO Year
- ALLR N/A
- AYTU N/A
- Fundamental
- Price
- ALLR $1.42
- AYTU $2.32
- Analyst Decision
- ALLR Strong Buy
- AYTU Strong Buy
- Analyst Count
- ALLR 1
- AYTU 3
- Target Price
- ALLR $9.25
- AYTU $9.17
- AVG Volume (30 Days)
- ALLR 327.2K
- AYTU 242.9K
- Earning Date
- ALLR 11-13-2025
- AYTU 11-12-2025
- Dividend Yield
- ALLR N/A
- AYTU N/A
- EPS Growth
- ALLR N/A
- AYTU N/A
- EPS
- ALLR N/A
- AYTU N/A
- Revenue
- ALLR N/A
- AYTU $66,382,000.00
- Revenue This Year
- ALLR N/A
- AYTU N/A
- Revenue Next Year
- ALLR N/A
- AYTU $19.03
- P/E Ratio
- ALLR N/A
- AYTU N/A
- Revenue Growth
- ALLR N/A
- AYTU 1.84
- 52 Week Low
- ALLR $0.61
- AYTU $0.95
- 52 Week High
- ALLR $2.35
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- ALLR 40.01
- AYTU 51.39
- Support Level
- ALLR $1.40
- AYTU $2.23
- Resistance Level
- ALLR $1.53
- AYTU $2.42
- Average True Range (ATR)
- ALLR 0.12
- AYTU 0.15
- MACD
- ALLR -0.03
- AYTU 0.01
- Stochastic Oscillator
- ALLR 1.49
- AYTU 53.23
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.